Search Results

Press Releases

ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

October 21, 2024

·

9 min read

Skin lesions of prurigo nodularis, including

Immunology and inflammation

Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis

The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.

August 13, 2024

·

2 min read

·

Tristan Manalac

FDA

The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market

September 9, 2024

·

4 min read

Press Releases

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

September 17, 2024

·

5 min read

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.

March 10, 2024

·

9 min read

Drug Development

TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously

Galderma announced positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines, either alone or simultaneously.

January 17, 2024

·

10 min read

Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.

February 14, 2024

·

11 min read

CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.

February 14, 2024

·

12 min read

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

February 28, 2024

·

6 min read

Press Releases

EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations

September 25, 2024

·

10 min read